Levemir

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2004-2016
02420042016

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
Peripheral insulin resistance is a key component of metabolic syndrome associated with obesity, dyslipidemia, hypertension, and… (More)
Is this relevant?
2012
2012
AIMS The aim of this analysis is to determine the timing of insulin initiation in routine clinical practice, especially in… (More)
Is this relevant?
2012
2012
A 52-year-old insulin-dependant diabetic man presented to the Emergency Department 2 hours after a deliberate massive overdose of… (More)
Is this relevant?
Review
2012
Review
2012
There is an association between insulin analogues, glargine, lispro and aspart and the incidence of malignancies. A 76 year-old… (More)
Is this relevant?
2009
2009
OBJECTIVE To discuss the design and baseline data of the Lantus (sanofi-aventis, Paris, France) versus Levemir (Novo Nordisk A/S… (More)
Is this relevant?
2009
2009
OBJECTIVE This study was conducted to quantify the long-term cost-effectiveness of insulin detemir (Levemir) versus intermediate… (More)
Is this relevant?
2007
2007
The search for target analytes to uncover the misuse of long acting insulin analogues (Lantus, Insulin Glargine; Levemir, Insulin… (More)
Is this relevant?
Review
2007
Review
2007
Forty-three case reports of patients with type 2 diabetes who were treated with insulin detemir (Levemir, Novo Nordisk A/S… (More)
Is this relevant?
Review
2006
Review
2006
Insulin detemir (Levemir) is a soluble long-acting human insulin analogue acylated with a 14-carbon fatty acid. Insulin detemir… (More)
Is this relevant?
2005
2005
Insulin detemir (Levemir) is a soluble long acting human insulin analogue acylated with a 14-carbon fatty acid. The fatty acid… (More)
Is this relevant?